Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Glipizide Extended-Release Tablets

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

39 API Suppliers, 18 USDMF, 5 CEP/COS, 5 EU WC, 18 NDC API, 18 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

107 FDF Dossiers, 73 FDA Orange Book, 11 Europe, 4 Australia, 1 South Africa, 18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 10MG, TABLET, EXTENDED RELEASE;ORAL - 2.5MG, TABLET, EXTENDED RELEASE;ORAL - 5MG

RELATED EXCIPIENT COMPANIES

1 Minakem, 6 Evonik, 5 SPI Pharma, 16 DKSH, 6 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 3 Kirsch Pharma, 1 ACG Worldwide, 7 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 1 Avesta Pharma, 32 BASF, 2 CD Formulation, 2 Clariant, 14 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 2 Finar, 12 Gangwal Chemicals, 13 Ideal Cures, 4 Ingredion Pharma Solutions, 26 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 21 Roquette, 14 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

73 Coating Systems & Additives, 68 Fillers, Diluents & Binders, 40 Controlled & Modified Release, 35 Solubilizers, 33 Thickeners and Stabilizers, 30 Disintegrants & Superdisintegrants, 30 Granulation, 30 Direct Compression, 28 Lubricants & Glidants, 28 Topical, 21 Film Formers & Plasticizers, 18 Parenteral, 14 Co-Processed Excipients, 11 Taste Masking, 10 Emulsifying Agents, 10 Rheology Modifiers, 9 Chewable & Orodispersible Aids, 7 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

21 News #PharmaBuzz

21 News #PharmaBuzz

GLOBAL SALES INFORMATION

20 US Medicaid Prescriptions, 13 Regulatory FDF Prices

MARKET PLACE

5 APIs, 2 FDF Dossiers

REF. STANDARDS & IMPURITIES

5 EDQM, 17 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Sri Krishna Pharmaceuticals	India	SRI KRISHNA PHARMACEUTICALS LIMITED Hyderabad IN	CEP 2014-070 - Rev 01	Glipizide	2025-01-23	Valid	Chemical		906
29/11/2025	Taizhou Highsun Pharmaceutical Co.,Ltd.	China	TAIZHOU HIGHSUN PHARMACEUTICAL CO., LTD. Duqiao CN	R1-CEP 2008-210 - Rev 00	Glipizide	2015-02-17	Withdrawn by EDQM Failure to CEP procedure	Chemical	2021-09-23	906

Glipizide Extended-Release Tablets

Glipizide Extended-Release Tablets

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

39 API Suppliers

18 USDMF

5 CEP/COS

5 EU WC

18 NDC API

18 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

107 FDF Dossiers

73 FDA Orange Book

11 Europe

4 Australia

1 South Africa

18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 10MG

TABLET, EXTENDED RELEASE;ORAL - 2.5MG

TABLET, EXTENDED RELEASE;ORAL - 5MG

RELATED EXCIPIENT COMPANIES

1 Minakem

6 Evonik

5 SPI Pharma

16 DKSH

6 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

3 Kirsch Pharma

1 ACG Worldwide

7 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

1 Avesta Pharma

32 BASF

2 CD Formulation

2 Clariant

14 Corel Pharma Chem

7 DFE Pharma

1 Esteem Industries

2 Finar

12 Gangwal Chemicals

13 Ideal Cures

4 Ingredion Pharma Solutions

26 Kerry

3 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

14 Microlex e.U

1 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

3 Novo Excipients

4 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

21 Roquette

14 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

11 Sigachi Industries

4 Silverline Chemicals

2 The Dow Chemical Company

TABLET;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 2.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons